Bułgaria -
bułgarski -
БАБХ (Българска агенция по безопасност на храните)
t.m.p.s. inj.
kepro b.v. - Триметоприм; Сулфаметоксазол - инжекционен разтвор - 40 mg/ml; 200 mg/ml - говеда, коне, прасета
Bułgaria -
bułgarski -
БАБХ (Българска агенция по безопасност на храните)
tetravet l.a. 200 mg
ceva sante animale - Окситетрациклин - инжекционен разтвор - 200 mg - говеда, овце, свине
Bułgaria -
bułgarski -
БАБХ (Българска агенция по безопасност на храните)
agavac bio 0.350 eu/ml
БИОСФЕРА ФАРМ ЕООД - agalactiae микоплазма, щам ag 6, инактивированная - инжекционна суспензия - 0.350 eu/ml - кози, овце
Unia Europejska -
bułgarski -
EMA (European Medicines Agency)
nubeqa
bayer ag - darolutamide - Новообразувания На Простатата, Кастраци-Упорит - Ендокринна терапия - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
Bułgaria -
bułgarski -
БАБХ (Българска агенция по безопасност на храните)
pen/strep bg 20/20 inj.
ДОНЕВ ЕООД - benzylpenicillin procaine, dihydrostreptomycin sulfate - инжекционна суспензия - 200.000 iu/ml; 200.0 mg/ml - говеда, коне, котки, кучета, овце, свине
Unia Europejska -
bułgarski -
EMA (European Medicines Agency)
cabazitaxel accord
accord healthcare s.l.u. - кабазитаксел - Новообразувания На Простатата, Кастраци-Упорит - Антинеопластични средства - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Bułgaria -
bułgarski -
БАБХ (Българска агенция по безопасност на храните)
bravoxin suspension for injection for cattle and sheep
intervet international b.v - c. perfringens type a () toxoid; c. perfringens type b & c () toxoid; c. perfringens type d () toxoid; c. chauvoei whole culture, inactivated; c. novyi toxoid; c. septicum toxoid; c. tetani toxoid; c. sordellii toxoid; c. haemolyticum toxoid - инжекционна суспензия - В ml: c. perfringens type a () toxoid 0,5 iu#; c. perfringens type b & c () toxoid 18,2 iu*; c. perfringens type d () toxoid 5,3 iu*; c. chauvoei whole culture, inactivated 90% защита**; c. novyi toxoid 3,8 iu*; c. septicum toxoid 4,6 iu*; c. tetani toxoid 4,9 iu*; c. sordellii toxoid 4,4 u1; c. haemolyticum toxoid 17,4 u# - говеда, овце
Bułgaria -
bułgarski -
БАБХ (Българска агенция по безопасност на храните)
eprecis 20 mg/ml solution for injection for cattle, sheep, goats 20 mg/ml
Сева Анимал Хелт България ЕООД - eprinomectin - инжекционен разтвор - 20 mg/ml - говеда, кози, овце
Unia Europejska -
bułgarski -
EMA (European Medicines Agency)
abiraterone accord
accord healthcare s.l.u. - абаратер ацетат - Простатни неоплазми - Ендокринна терапия - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Unia Europejska -
bułgarski -
EMA (European Medicines Agency)
abiraterone krka
krka, d.d., novo mesto - абаратер ацетат - Простатни неоплазми - Ендокринна терапия - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.